SEC Company Response from BIOCRYST PHARMACEUTICALS (BCRX) — Dec 16, 2025
BIOCRYST PHARMACEUTICALS INC
Date: Dec. 16, 2025 · CIK: 0000882796 · Accession: 0001140361-25-045599
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291678
Letter
Re:
December 16, 2025
VIA EDGAR
United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill
BioCryst Pharmaceuticals, Inc.
Amendment No. 1 to Registration Statement on Form S-4
Filed December 15, 2025
File No. 333-291678
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCryst Pharmaceuticals, Inc. hereby requests that the effective date of its Registration Statement on Form S-4 (File No. 333-291678) be accelerated by the Securities and Exchange Commission to December 18, 2025 at 9:00 a.m., Eastern Time, or as soon as practicable thereafter.
Should you have any questions or comments regarding the foregoing, please contact Matthew T. Gehl of Covington & Burling LLP at (212) 841-1113. In addition, please notify Mr. Gehl by telephone when this request for acceleration has been granted.
Sincerely,
BIOCRYST PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm December 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: BioCryst Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-4 Filed December 15, 2025 File No. 333-291678 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCryst Pharmaceuticals, Inc. hereby requests that the effective date of its Registration Statement on Form S-4 (File No. 333-291678) be accelerated by the Securities and Exchange Commission to December 18, 2025 at 9:00 a.m., Eastern Time, or as soon as practicable thereafter. Should you have any questions or comments regarding the foregoing, please contact Matthew T. Gehl of Covington & Burling LLP at (212) 841-1113. In addition, please notify Mr. Gehl by telephone when this request for acceleration has been granted. Sincerely, BIOCRYST PHARMACEUTICALS, INC. By: /s/ Jon P. Stonehouse Jon P. Stonehouse Chief Executive Officer cc: Alane Barnes, BioCryst Pharmaceuticals, Inc. Ben Harshbarger, Astria Therapeutics, Inc. Jack S. Bodner, Covington & Burling LLP Andrew W. Ment, Covington & Burling LLP Matthew T. Gehl, Covington & Burling LLP Charles A. Dobb, Covington & Burling LLP Rosemary G. Reilly, Sidley Austin LLP John H. Butler, Sidley Austin LLP Sally Wagner Partin, Sidley Austin LLP